Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.
Study Goal
The researchers aimed to consolidate current findings on psilocybin's pharmacology, safety profile, and clinical applications, particularly for treating depression and other mental health conditions.
Results Summary
Psilocybin showed promise for treating major depressive disorder and treatment-resistant depression, with remission rates of 42%-57% in initial studies and 25%-29% in larger trials. It also demonstrated sustained benefits for substance use disorders and end-of-life anxiety, though some cases of suicidal ideation were reported.
Population
Patients with major depressive disorder, treatment-resistant depression, substance use disorders, and end-of-life anxiety.
Effective Dosage
Single 25 mg dose mentioned in the largest clinical trial.
Duration
Effects were monitored for up to 12 weeks post-dose, with some benefits lasting months to years.
Interactions
Selective serotonin reuptake inhibitors may blunt hallucinogenic effects but potentially enhance antidepressant effects.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
psilocybin | no change | safety profile | - | - | generally safe | #1 |
psilocybin | increase | nausea and headache | - | transient | most common adverse effects are | #2 |
psilocybin | increase | suicidal ideation | participants in the largest clinical trial to date | 7 cases | reported cases of | #3 |
selective serotonin reuptake inhibitors | decrease | the hallucinogenic qualities of psilocybin | - | - | may blunt | #4 |
selective serotonin reuptake inhibitors | increase | antidepressant effects of psilocybin | - | - | may enhance | #5 |
psilocybin-assisted therapy | decrease | major depressive disorder and treatment-resistant depression | patients | 42%-57% | patients underwent remission after | #6 |
psilocybin | decrease | substance use disorders and end-of-life anxiety | - | sustained for months and sometimes years after 1 or 2 doses | can manage | #7 |
psilocybin | decrease | depression | more than 100 depressed participants in larger Phase II trials | 25%-29% | much smaller remission rate | #8 |
psilocybin | decrease | depressive symptoms | participants in larger Phase II trials | - | causes a significant reduction in | #9 |
BACKGROUND: The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. AREAS OF UNCERTAINTY: Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is generally safe. The most common adverse effects are nausea and headache, yet both tend to be transient. Serious adverse events can generally be avoided in controlled settings such as clinical trials. However, in the largest clinical trial to date, there were a total of 7 reported cases of suicidal ideation, up to 12 weeks after receiving a single 25 mg dose of psilocybin. That being said, all 7 cases did not respond to the treatment. Although selective serotonin reuptake inhibitors may blunt the hallucinogenic qualities of psilocybin, preliminary research suggests that they may enhance its antidepressant effects. THERAPEUTIC ADVANCES: In clinical trials, psilocybin has shown promise for treating major depressive disorder and treatment-resistant depression. Initial studies indicated that 42%-57% of patients underwent remission after psilocybin-assisted therapy, which suggests that psilocybin is more effective than existing antidepressant medications. Clinical data have also demonstrated that psilocybin can manage substance use disorders and end-of-life anxiety with clinical outcomes that are sustained for months and sometimes years after 1 or 2 doses. LIMITATIONS: However, larger Phase II trials with more than 100 depressed participants have shown a much smaller remission rate of 25%-29%, though these studies still observed that psilocybin causes a significant reduction in depressive symptoms. CONCLUSIONS: Aside from ketamine, psilocybin is the most clinically well-researched psychedelic drug, with trials that have enrolled hundreds of participants and multiple therapeutic applications. Phase III trials will determine whether psilocybin lives up to the promise that it showed in previous clinical trials.